CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Dilated cardiomyopathy: so many cardiomyopathies! The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure

Expert Opinionhttps://academic.oup.com/eurheartj/article-abstract/41/39/3784/5686010?redirectedFrom=fulltext

JOURNAL:Eur Heart J. Article Link

Dilated cardiomyopathy: so many cardiomyopathies!

G Sinagra, PM Elliott, M Merlo et al. Keywords: DCM; LV; HF

ABSTRACT

The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk.